Press release
HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight
The HER2+ Gastric Cancer market is projected to grow significantly in the 7MM, which includes the United States, EU4-Germany, France, Italy, and Spain-the United Kingdom, and Japan. This growth is attributed to several factors, including the increasing incidence of HER2+ Gastric Cancer, advances in research and development, and innovations in the treatment landscape by various key HER2+ Gastric Cancer companies such as Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer/Loxo Oncology, Eli Lilly and Company, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Ltd., Shanghai Henlius Biotech, Bristol-Myers Squibb, Jiangsu HengRui Medicine, Seagen, MacroGenics/Zai Lab, Merck Sharp & Dohme Corp., Merus N.V., OncXerna Therapeutics, Inc., Innovent Biologics, and others.
DelveInsight's latest report, "HER2+ Gastric Cancer Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", provides an in-depth analysis of the evolving treatment landscape, epidemiological trends, and market dynamics across the 7MM. The report highlights advancements in HER2-targeted therapies, immunotherapy combinations, and antibody-drug conjugates (ADCs) that are poised to transform patient outcomes in this aggressive cancer subtype.
Download the report to understand which factors are driving the HER2 Positive Gastric Cancer therapeutic market @ HER2 Positive Gastric Cancer Market Trends [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The gastric cancer incidence varies considerably across different geographic regions, with Eastern Asian countries, including Japan, reporting the highest incidence rates. The US also accounts for a notable proportion of gastric cancer cases, representing 1.5% of all new cancer diagnoses each year.
As per DelveInsight's estimates, the HER2+ gastric cancer market is projected to grow significantly from 2024 to 2034. This growth is driven by a rising incidence, improved diagnostic protocols, and expanding therapeutic options. Several pipeline drugs for HER2+ gastric cancer, including Evorpacept (ALX Oncology), Zanidatamab (Jazz Pharmaceuticals), IAM1363 (Iambic Therapeutics), ELVN 002 (Enliven Therapeutics), ARX788 (Ambrx), and Rilvegostomig (AstraZeneca), are in development.
Discover evolving trends in HER2+ Gastric Cancer patient pool forecasts @ HER2+ Gastric Cancer Epidemiology Analysis [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Additionally, recent therapy approvals such as ENHERTU (Daiichi Sankyo and AstraZeneca), OPDIVO (Bristol Myers Squibb), trastuzumab (Roche), KEYTRUDA (Merck & Co., Inc.), and AIDIXI (RemeGen) are further fueling the market growth. The FDA has also approved HLX02 (Henlius Biotech), a HERCEPTIN biosimilar, as an adjuvant therapy for patients with HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Despite the active landscape of HER2+ gastric cancer therapeutics, there is a continued need for the development of novel drugs that are more effective and less toxic. DelveInsight's leading oncology consultant notes, "One of the major challenges in treating HER2-positive gastric cancer is the development of resistance to existing therapies. It is indicated that up to 70% of patients who progress after the initial trastuzumab treatment may lose HER2 expression or acquire genetic alterations that render them resistant to further anti-HER2 therapies." This underscores the potential impact of emerging therapies in revolutionizing HER2-positive gastric cancer treatment.
Unlock which emerging HER2+ gastric cancer drug is expected to capture the largest market share in 7MM by 2034. Visit the HER2+ gastric cancer Market Insights [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Recent developments, such as the US FDA's Breakthrough Therapy designation given to Zanidatamab in November 2024 and significant clinical trial updates for Evorpacept, highlight the momentum in the field.
In summary, the factors mentioned above are contributing to the significant expansion of the HER2+ gastric cancer market, suggesting a future where improved screening, innovative drug delivery systems, and novel therapies will transform the management of a disease that continues to challenge clinicians and patients alike.
Table of Contents
1.
Key Insights
2.
Executive Summary of HER2+ Gastric Cancer
3.
HER2+ Gastric Cancer Competitive Intelligence Analysis
4.
HER2+ Gastric Cancer: Market Overview at a Glance
5.
HER2+ Gastric Cancer: Disease Background and Overview
6.
Patient Journey
7.
HER2+ Gastric Cancer Epidemiology and Patient Population
8.
Treatment Algorithm, Current Treatment, and Medical Practices
9.
HER2+ Gastric Cancer Unmet Needs
10.
Key Endpoints of HER2+ Gastric Cancer Treatment
11.
HER2+ Gastric Cancer Marketed Products
12.
HER2+ Gastric Cancer Emerging Therapies
13.
HER2+ Gastric Cancer: Seven Major Market Analysis
14.
Attribute analysis
15.
7MM: Market Outlook
16.
Access and Reimbursement Overview of HER2+ Gastric Cancer
17.
KOL Views
18.
HER2+ Gastric Cancer Market Drivers
19.
HER2+ Gastric Cancer Market Barriers
20.
Appendix
21.
DelveInsight Capabilities
22.
Disclaimer
23.
About DelveInsight
Related Reports
HER2 Positive Gastric Cancer Pipeline Insight [https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
HER2 Positive Gastric Cancer Pipeline Insight provides comprehensive insights about the HER2 Positive Gastric Cancer pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the HER2 Positive Gastric Cancer companies, including Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc, Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, among others.
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=her2-gastric-cancer-market-to-witness-upsurge-in-growth-during-the-forecast-period-20242034-examine-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight here
News-ID: 3907580 • Views: …
More Releases from ABNewswire
EleganceBrew Reports Record Holiday Sales Growth as Health-Conscious Consumers C …
EleganceBrew celebrates unprecedented holiday season success with triple-digit growth in wellness tea and premium coffee sales. The company attributes its performance to increasing consumer preference for gifts that combine luxury with health benefits, particularly among millennials and Gen Z shoppers.
As the holiday shopping season reaches its peak, EleganceBrew is thrilled to announce exceptional sales performance that has exceeded all projections, with particular strength in its wellness-focused product lines and curated…
From Heritage to Modern Elegance: Chow Sang Sang Redefines Meaningful Jewellery
Image: https://www.abnewswire.com/upload/2025/12/2ef0a71ce13c92816c1d174f1f64452a.jpg
Jewellery is more than a fashion statement-it is an emotional expression, a mark of identity, and a cherished symbol of life's most meaningful occasions. Whether you're celebrating love, honouring tradition, or elevating everyday elegance, choosing the right jewellery matters. This is where Chow Sang Sang shines as a brand [https://tracking.icubeswire.co/aff_c?offer_id=5781&aff_id=11853&url_id=11656] that consistently delivers excellence, making it the best choice every time you shop for fine jewellery.
With a legacy spanning…
Tieks Honors the Success of Its Pink Ribbon Campaign and Introduces the Holiday …
Image: https://www.abnewswire.com/upload/2025/12/a196054eb455ee2812f6daa4ed65cf87.jpg
LOS ANGELES - Tieks, the Los Angeles based luxury ballet flat maker, celebrates the success of its Pink Ribbon campaign and presents the Holiday Gift Calendar 2025. The calendar is created to share the spirit of giving through design, craftsmanship, and care.
Pink Ribbon Tieks [https://tieks.com/pink-ribbon-ballet-flats] is Tieks' first-ever embellished style featuring a symbolic leather bow on the iconic Ballerina Pink Tieks. This limited-edition honors Breast Cancer Awareness Month by…
OSpark.ai Launches as a Free All-Round AI Assistant Merging Smart Tools, Creativ …
San Francisco - OctoPaul [https://octopaul.com/] today announced the launch of OSpark.ai [https://ospark.ai/?utm_source=tobeseen&utm_medium=geo&utm_campaign=v10] - the free all-round AI assistant that combines smart searches, web/doc summarization, and image recognition with AI-driven image generation and podcast creation, all while giving unlimited access to top-tier LLMs. It's like having a 24/7 sidekick that simplifies work, play, and daily tasks with seamless AI magic - no subscriptions, no hidden fees, just pure convenience.
Image: https://www.abnewswire.com/upload/2025/12/5041a6803bc9d15e014bce9659717adc.jpg
Whether a…
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
